Vaxcyte stock holds near recent highs as OPUS-1 Phase 3 data window narrows

Published on 09/17/2026 at 16:29 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Vaxcyte stock closed at USD 58.77 on Nasdaq on September 16, 2026, after a near-90 percent one-year gain. The company now guides OPUS-1 Phase 3 VAX-31 adult data to the end of October 2026, sharpening its key catalyst window.

PCVX, US92242T1016, Illustration mit AI erstellt.

Vaxcyte, Inc. stock (ISIN US92242T1016) ended the September 16, 2026 Nasdaq session at USD 58.77, leaving the pneumococcal vaccine developer near the upper end of its recent trading range after a strong one-year performance of about 91 percent.

Phase 3 OPUS-1 data window tightened

According to Yahoo Finance on September 3, 2026, Vaxcyte has guided that topline safety, tolerability and immunogenicity data from its VAX-31 adult Phase 3 OPUS-1 trial are now expected by the end of October 2026, a refinement from earlier guidance that had pointed only to the fourth quarter.

The same article notes that Vaxcyte recently strengthened its leadership team by appointing two new C-suite executives with extensive pharmaceutical experience, aiming to support the transition from late-stage development toward potential commercialization of VAX-31.Yahoo Finance

Stock performance and market backdrop

Per data compiled by Seeking Alpha as of the close on September 16, 2026, Vaxcyte stock traded at USD 58.77 on Nasdaq, down 0.44 dollars or 0.74 percent on the day, while its trailing one-year return stood at approximately 91.00 percent, highlighting how the shares have significantly outperformed over the past twelve months despite the modest latest pullback.

The same overview shows that over the last nine months the stock gained about 33.54 percent, compared with a 19.47 percent advance over three months and an 8.48 percent increase over six months, indicating that the strongest momentum has come over the longer one-year period rather than in the very short term.Seeking Alpha

Upcoming catalysts beyond OPUS-1

As Yahoo Finance reports, Vaxcyte expects additional data from the broader VAX-31 program in later periods: results from the OPUS-2 and OPUS-3 adult trials, which focus on co-administration with influenza vaccines and boosting in previously vaccinated individuals, are guided to the first half of 2027, while infant Phase 2 data for VAX-31 are also anticipated in that same window.

These staggered readouts mean that while the end-of-October 2026 OPUS-1 topline data are the immediate driver for Vaxcyte stock, investors face a sequence of further clinical milestones extending into 2027 that will collectively shape the long-term outlook for the company’s pneumococcal conjugate vaccine franchise.Yahoo Finance

Risk perspective: short interest and macro volatility

According to Yahoo Finance, short interest in Vaxcyte shares recently stood at about 10.14 percent of the free float, a level that the outlet characterizes as indicating notable skepticism from some market participants rather than just routine hedging.

At the same time, broader U.S. equity indices have shown renewed volatility after the latest Federal Reserve interest rate increase, with reports on September 17, 2026 highlighting declines of more than 1 percent in the Dow Jones Industrial Average and smaller losses in the Nasdaq Composite, which can add an additional layer of risk for growth-oriented healthcare names such as Vaxcyte.Emirates News Agency

Vaxcyte stock price level

Vaxcyte stock closed at USD 58.77 on Nasdaq on September 16, 2026, with the venue serving as the primary listing and reference price for the shares, and the one-year gain of approximately 91.00 percent leaving the stock well above its levels of late 2025 even after the latest 0.74 percent daily decline.